April Armstrong, MD, MPH

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of polypharmacy.

An independence-minded 72-year-old with hand arthritis and missed oral doses forces a reassessment of what a workable psoriasis regimen looks like once dexterity and daily routine become limiting factors.

Speed of onset and long-term durability are often treated as competing priorities. Dr. Armstrong argues they are not mutually exclusive, and details how cardiometabolic comorbidities and how emerging incretin-therapy data may extend treatment options beyond skin clearance alone.

With more biologic classes available than ever, selecting a first-line agent for a treatment-naive patient increasingly depends on comorbidity screening, lifestyle fit, and realistic expectations rather than efficacy data alone.

A systemic-naive roofer with extensive plaque psoriasis and cardiometabolic risk illustrates why compliance history, not just disease severity, should shape the first conversation about moving beyond topical therapy.

As biologics multiply, the boundary between topical failure and systemic eligibility remains contested. Dr. Armstrong outlines the severity thresholds, comorbidities, and quality-of-life factors that most reliably justify escalating plaque psoriasis therapy.

April Armstrong, MD, MPH, discusses the role of itch as a key driver of psoriasis burden and shows how next-generation oral TYK2 inhibitors like envudeucitinib provide rapid symptom relief and meaningful improvements in quality of life.

April Armstrong, MD, MPH, highlights envudeucitinib as a next-generation oral TYK2 inhibitor that delivers biologic-level efficacy and strong safety, expanding treatment options for patients with moderate to severe psoriasis.

April Armstrong, MD, MPH, reframes psoriasis as a systemic inflammatory disease and highlights a shift toward earlier systemic treatment, with emerging oral therapies like TYK2 inhibitors offering improved efficacy and safety.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.